Roth Capital Increases BioLineRx Price Target to $5.00 (BLRX)
Analysts at Roth Capital increased their price objective on shares of BioLineRx (NASDAQ:BLRX) from $3.00 to $5.00 in a research report issued to clients and investors on Tuesday, Analyst Ratings Network reports. The firm currently has a “buy” rating on the stock. Roth Capital’s price objective indicates a potential upside of 78.57% from the company’s current price.
Separately, analysts at Aegis reiterated a “buy” rating on shares of BioLineRx in a research note to investors on Monday, September 9th.
Shares of BioLineRx (NASDAQ:BLRX) traded up 5.26% during mid-day trading on Tuesday, hitting $2.80. The stock had a trading volume of 910,374 shares. BioLineRx has a 52-week low of $1.55 and a 52-week high of $5.10. The stock has a 50-day moving average of $2.19 and a 200-day moving average of $1.86. The company’s market cap is $64.3 million.
BioLineRx (NASDAQ:BLRX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.02) earnings per share for the quarter.
BioLineRX Ltd. is an Israel-based company engaged in identifying and following the critical pathway to commercialization of therapeutic compounds.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.